CYP2C9 rs17376848: What Your Genotype Means
The rs17376848 variant is a genetic polymorphism located in the CYP2C9 gene. It is currently being studied for its potential role in the metabolism of various medications, including certain anticancer drugs.
What each genotype means
Typical metabolic profile
This genotype is considered the common or reference form of the CYP2C9 gene in many populations. It is associated with standard enzyme activity for the metabolism of various drugs, including certain anticancer therapeutics. As with any medication, please consult your clinician regarding your specific treatment and dosing needs.
This is the most common genotype observed in the general population.
Potential altered metabolism
This genotype includes one copy of the variant, which is being studied for its role in the metabolism of anticancer drugs, particularly in Nigerian cohorts. The clinical significance of this specific variant remains an area of active research, and its impact on drug efficacy or safety is not yet fully established. Please discuss your medication management with your healthcare provider.
The frequency of this genotype is variable and depends significantly on the specific ancestral background of the population studied.
Potential altered metabolism
This genotype represents the homozygous variant form, which is currently under investigation for its potential influence on drug metabolism. Because evidence regarding the clinical impact of this variant is still emerging, it is unclear how it may affect your response to specific medications. Always coordinate with your medical team to ensure your treatment plan is appropriate for your genetic profile.
This genotype is rare and its prevalence varies significantly across different global populations.
Understanding the rs17376848 Variant
The rs17376848 variant is a single nucleotide polymorphism (SNP) situated within the CYP2C9 gene. This gene is responsible for producing an enzyme that belongs to the cytochrome P450 family, which is essential for the metabolism of a wide range of drugs, including anticoagulants, nonsteroidal anti-inflammatory drugs, and certain chemotherapy agents. Genetic variations in CYP2C9 can lead to differences in enzyme activity, potentially affecting how quickly or slowly a person processes these medications. By studying variants like rs17376848, researchers aim to better understand the genetic basis for the variability in drug response observed among patients. While this variant is documented in scientific literature, its specific functional impact on the CYP2C9 enzyme is still being characterized. It is important to recognize that genetic factors are only one piece of the puzzle, as environmental and clinical factors also influence drug metabolism.
Research and Clinical Associations
Research into rs17376848 has focused on its role in pharmacogenomics, particularly within specific cohorts such as those in Nigeria, to assess its influence on the metabolism of anticancer drugs. The evidence strength for this variant is currently classified as moderate, indicating that while there is scientific interest and some observed data, it is not yet a standard marker for clinical decision-making. Pharmacogenetic research seeks to identify how such variants might predict adverse drug reactions or therapeutic efficacy. However, because the relationship between this specific variant and clinical outcomes is complex and potentially influenced by other genetic and non-genetic factors, it is not currently used to guide routine clinical dosing. Ongoing studies are necessary to determine the full extent of its impact and whether it should be incorporated into future personalized medicine strategies for patients receiving specific chemotherapy treatments.
Interpreting Your Genetic Information
If you have information regarding your rs17376848 genotype, it is crucial to view this data as educational rather than diagnostic. Genetic associations are based on statistical findings in research populations and do not necessarily predict how an individual will respond to a specific medication. Many variables, such as your overall health, other medications you may be taking, and your lifestyle, significantly influence drug metabolism. You should never use genetic information to make changes to your prescribed medication regimen, such as altering doses or discontinuing treatment. If you have questions about how your genetics might influence your response to a medication, the most appropriate step is to consult with your clinician or pharmacist. They can provide guidance based on your unique medical history and the current clinical standards of care, ensuring that any decisions regarding your treatment are safe and evidence-based.
How common is this variant?
The frequency of the rs17376848 variant is variable across different ancestral populations, reflecting the diversity of genetic profiles globally.
Frequently asked questions
What is the CYP2C9 gene?
The CYP2C9 gene provides instructions for making an enzyme that is part of the cytochrome P450 system. This system is primarily responsible for breaking down and eliminating many different types of drugs from the body.
Can I use this information to change my medication?
No. You should never change your medication dosage or stop taking a prescribed drug based on genetic test results. Always consult your doctor or pharmacist before making any changes to your treatment plan.
Is rs17376848 a diagnostic test?
No, rs17376848 is a genetic variant, not a diagnostic test. It is studied for its potential role in drug metabolism, but it is not used to diagnose any specific disease or condition.
Where can I find more information about pharmacogenomics?
You can find reliable information on pharmacogenomics through resources like the Clinical Pharmacogenetics Implementation Consortium (CPIC) or MedlinePlus Genetics, which provide evidence-based summaries on how genes affect drug response.
Sources & further reading
Educational information only, last refreshed 11/6/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs17376848?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in CYP2C9
This variant is investigated for its potential impact on the efficacy and safety of anticancer therapeutics in underrepresented populations.
Rare variant in the CYP2C9 gene potentially impacting enzyme activity and drug metabolism; clinical significance requires further validation.
Missense mutation defining the CYP2C9*5 allele that dramatically lowers metabolic activity towards oral anticoagulants and anti-epileptic medications.
Coding variant conferring the CYP2C9*3 allele (often mislabeled as *4 in older literature) with decreased enzymatic activity affecting clearance of drugs such as warfarin and phenytoin.
A rare variant in the CYP2C9 gene that may impact the metabolism of various clinical drugs.
The CYP2C9*2 variant (p.Arg144Cys) results in reduced enzymatic activity, significantly impacting the metabolism and required dosing of substrates such as warfarin and irbesartan.